FIG.1

% with > Grade 1

Symptom Categories

Headache Myalgia Chills GI Gen. rash

DEN-1 n=12
DEN-2 n=12
DEN-3 n=13
DEN-4 n=12
Tetrav n=4
YF 17D n=4

FIG.2

FIG.3

Formulation DEN1-2-3-4	No. Subjects	Mean Reactogenicity Index			No. viremic (cell culture)	Neutralizing Antibody to ≥ 3 serotypes
		1st dose	2nd dose	3rd dose		
LLLL	3	5	1	ND	1/3	2/3
HLLL	4	32	4	ND	3/4	4/4
LHLL	3	2	1	ND	3/3	0/3
LLLH	3	3	2	ND	1/3	0/3
LLHL	4	11	0	ND	4/4	1/4
LHLH	3	4	2	ND	1/3	0/3
HLHL	4	20	1	ND	4/4	2/4
LHHL	4	2	2	ND	0/4	1/4
LLHH	4	8	7	ND	2/4	1/4
HLLH	4	11	0	ND	2/4	4/4
HHLL	3	14	1	ND	3/3	3/3
LHHH	4	4	5	ND	0/4	1/4
HLHH	4	8	2	ND	1/4	3/4
HHLH	4	2	3	ND	1/4	4/4
HHHL	3	2	2	ND	0/3	2/3
HHHH	10	9	3	0	4/10	6/10
Total (mean)	64	(9)	(2)	(0)	47%	53%

* 5 subjects received dose at 4 months, 4 of these 5 seroconverted to ≥ 3 serotypes.
H = undiluted reconstituted vaccine, L = 1.5 log dilution of H.

FIG.4

Volunteer	Vaccine	Schedule	Serotypes Neutralizing Ab Seroconversion 30 days after:		
			Dose 1	Dose 2	Dose 3
33	Full-dose Tetraval.	0,1	1,2,3,4	1,2,3,4	ND
34	Full-dose Tetraval.	0,1	2	1,2	ND
35	Full-dose Tetraval.	0,1	1,2,3,4	1,2,3,4	ND
36	Full-dose Tetraval.	0,1	1	1,3	ND
37	Full-dose Tetraval.	0,1,4	1	1	1,2,3
38	Full-dose Tetraval.	0,4	1,2	1,2,3	ND
39	Full-dose Tetraval.	0,1,4	1,3,4	1,3	1,2,3,4
40	Full-dose Tetraval.	0,1,4	1	1	1,3
41	Full-dose Tetraval.	0,1,4	2	2	1,2,3,4
42	Full-dose Tetraval.	0,1	2	1,2	ND

FIG.5

Formulation DEN1-2-3-4	Volunteer No.	Reactogenicity Index		Viremia[1]		Serotypes Neutralizing Antibody 30 days after:	
		1st dose	2nd dose(1m)	1st dose	2nd dose	1st dose	2nd dose
HLLL	02-1	31	0	+	-	1,2,3,4	1,2,3,4
HLLL	02-2	23	0	-	-	1,2,3,4	1,3
HLLL	02-3	55	0	+	-	1,3,4	1,3
HLLL	02-4	18	0	+	+	1,2,3	1
HLLH	10-1	3	0	+	-	1,3	1,2,3,4
HLLH	10-2	0	0	-	-	1	1,2,3
HLLH	10-3	37	1	-	-	1,2,3	1,2,3
HLLH	10-4	5	0	+	-	1,2,3	1,3
HHLL	11-1	8	0	+	+	1,2,3	1
HHLL	11-2	20	2	+	-	1,2	1,2,3
HHLL	11-3	15	0	+	-	1,2,3	1,2
HLHH	13-1	6	4	-	-	1	1,4
HLHH	13-2	0	0	-	-	1,3,4	1,3,4
HLHH	13-3	4	0	-	-	1,2,*,4	1,2,*,4
HLHH	13-4	21	2	+	-	1,2,3,4	1,2,3,4
HHLH	14-1	0	0	-	-	1,2	1,2,3
HHLH	14-2	9	0	+	-	1,2,4	1,2,3,4
HHLH	14-3	0	2	-	-	None	1,2,3,4
HHLH	14-4	0	0	-	-	None	1,3,4
Mean		13.4	0.6				

1 by delayed plaque method on C6/36 and Vero

FIG.6A

Dengue 1

Legend:
- ● 10
- ○ 15
- ▼ 21
- ▽ 31

FIG.6B

Dengue 2

Legend:
- ● 5
- ○ 11
- ▼ 20

FIG.6C

Dengue 3

Legend:
- ● 3
- ○ 8
- ▼ 25
- ▽ 30

FIG.6D

Dengue 4

Legend:
- ● 12
- ○ 13

FIG.6E

Dengue 1

- ● 4
- ○ 16
- ▼ 22
- ▽ 29

FIG.6F

Dengue 2

- ● 2
- ○ 6
- ▼ 17

FIG.6G

Dengue 3

Legend:
- ● 9
- ○ 14
- ▼ 18
- ▽ 23

FIG.6H

Dengue 4

Legend:
- ● 7
- ○ 27

FIG.7A

Tetravalent Volunteer 33

- ● Dengue 1
- ○ Dengue 2
- ▼ Dengue 3
- ▽ Dengue 4

FIG.7B

Tetravalent Volunteer 36

- ● Dengue 1
- ○ Dengue 2
- Dengue 3

FIG.7C

Tetravalent Volunteer 34

Dengue 1
Dengue 2
Dengue 3
Dengue 4

FIG.7D

Tetravalent Volunteer 35

Dengue 1
Dengue 2
Dengue 3

FIG.8A

Granzyme B gel band intensity*

ID	Control	CD8dep	CD3dep	Unstim	Control	CD4dep
3	+++-	++++	+---	±--	++--	++--
4	++++	++++	++++			
10	++++	++++	+++-			
11	++++	++++	±--			
12*	++++	++++	±--			
13	++++	++++	+++-		++++	++++
15	++++	++++	+++-		++++	++++
16	+++-	++--	±--	----	++++	++++
17	++++	++++	+---	----	++++	++++
20	++--	++--	++--			
22	+++-	++--	±--	±--		
29	++++	++++	±--		++++	++++
31	++++	++++	+---	+---	++++	++++
33T	+++-	+---	----			
35T*	++++	++++	±--	±--		
36T	++++	++++	±--	±--		

FIG.8B

| | Control | CD8 dep | CD3 dep | |
| Ladder | 35T 12 | 35T 12 | 35T 12 | Neg |

100bp →